CareDx Inc (CDNA)vsIDEXX Laboratories Inc (IDXX)
CDNA
CareDx Inc
$79.81
-1.68%
HEALTHCARE · Cap: $4.59B
IDXX
IDEXX Laboratories Inc
$698.02
-0.65%
HEALTHCARE · Cap: $55.67B
Smart Verdict
WallStSmart Research — data-driven comparison
IDEXX Laboratories Inc generates 837% more annual revenue ($4.66B vs $497.40M). CDNA leads profitability with a 25.9% profit margin vs 25.4%. CDNA trades at a lower P/E of 36.9x. IDXX earns a higher WallStSmart Score of 61/100 (C+).
CDNA
Buy60
out of 100
Grade: C
IDXX
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$65.83
Current Price
$79.81
$13.98 discount
Margin of Safety
-45.1%
Fair Value
$447.14
Current Price
$698.02
$250.88 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 39.3% year-over-year
Earnings expanding 1067.0% YoY
Conservative balance sheet, low leverage
Keeps 26 of every $100 in revenue as profit
Every $100 of equity generates 63 in profit
Strong operational efficiency at 33.1%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 25 of every $100 in revenue as profit
Areas to Watch
Premium valuation, high expectations priced in
Trading at 9.0x book value
ROE of -2.6% — below average capital efficiency
Distress zone — elevated risk
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 29.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, EPS Growth, Debt/Equity. Profitability is solid with margins at 25.9% and operating margin at 8.5%. Revenue growth of 39.3% demonstrates continued momentum.
Bull Case : IDXX
The strongest argument for IDXX centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 25.4% and operating margin at 33.1%.
Bear Case : CDNA
The primary concerns for CDNA are P/E Ratio, Price/Book, Return on Equity.
Bear Case : IDXX
The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 47.6x leaves little room for execution misses.
Key Dynamics to Monitor
CDNA profiles as a growth stock while IDXX is a mature play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.38 — expect wider price swings.
CDNA is growing revenue faster at 39.3% — sustainability is the question.
IDXX generates stronger free cash flow (421M), providing more financial flexibility.
Bottom Line
IDXX scores higher overall (61/100 vs 60/100), backed by strong 25.4% margins. CDNA offers better value entry with a 70.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
IDEXX Laboratories Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?